23/10/2014 01:19:52 Free Membership Login

Accentia Biopharmaceuticals, (PN News (USOTC:ABPI)

DateTimeSource
Headline
10/16/20147:00AMIHNWNew Technologies in the Medical Market Space and Today’s Bounce Alert is Everlet, Inc.
Burton, MI - October 16, 2014 - InvestorsHub NewsWire - Accentia Biopharmaceuticals, Inc. (OTCBB: ABPI) is engaged in the business of commercializing patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening... More...>>
08/06/20135:26PMPRNUSSHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officer...
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI PR Newswire NEW YORK, Aug. 6, 2013 NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class... More...>>
07/31/201312:07PMPRNUSShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Accenti...
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Accentia Biopharmaceuticals, Inc. and Officers of Accentia and Biovest International, Inc. PR Newswire NEW YORK, July 31, 2013 NEW YORK, July 31, 2013 /PRNewswire/ -- Attorney Advertising --  Bronstein... More...>>
07/30/20136:35PMBWShapiro Haber & Urmy LLP & Liggio Benrubi PA Announce the Filing of a Class Action Lawsuit Against Accentia Biopharmaceutical...
Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (“Accentia”) (ABPI) and certain officers and directors of Accentia and Biovest International, Inc. (“Biovest”) (OTCQB:BVTI), a majority-owned subsidiary of Accentia, for violations of federal... More...>>
07/30/20136:35PMBWShapiro Haber & Urmy LLP & Liggio Benrubi PA Announce the Filing of a Class Action Lawsuit Against Accentia Biopharmaceutical...
Shapiro Haber & Urmy LLP and Liggio Benrubi PA filed a class action on July 26, 2013 against Accentia Biopharmaceuticals, Inc. (“Accentia”) (ABPI) and certain officers and directors of Accentia and Biovest International, Inc. (“Biovest”) (OTCQB:BVTI), a majority-owned subsidiary of Accentia, for violations... More...>>
03/07/20134:45PMBWBiovest Files Recapitalization Plan to Strengthen Balance Sheet & Advance Commercialization Strategy for BiovaxID™ Cancer V...
Biovest International, Inc. (OTCQB:BVTI) today reported that the Company has filed a petition for protection under Chapter 11 of the U.S. Bankruptcy Code and a Plan of Reorganization (the “Plan”) seeking to implement a restructuring of its balance sheet that would eliminate approximately $44 million in senior secured... More...>>
12/04/20122:45PMBWBiovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting
Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that Biovest will present at the Lymphoma Coalition’s annual patient advocacy event leading up to the American Society of Hematology (ASH) Annual Meeting in Atlanta, Dec... More...>>
09/20/20128:15AMBWBiovest Conducts Meeting with EMA Advancing Process to Seek EU Approval for Cancer Vaccine
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today reported milestone achievements advancing BiovaxID™, Biovest’s personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, including a recently conducted regulatory meeting... More...>>
09/11/20127:45AMBWBiovest Names Lymphoma Key Opinion Leader from MD Anderson Cancer Center to Scientific Advisory Board
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that it appointed Sattva S. Neelapu, M.D., Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center to Biovest’s... More...>>
08/14/20127:15AMBWBiovest Conducts End of Phase III Review with FDA of BiovaxID™ as Consolidation Therapy in Non-Hodgkin’s Lymphoma
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that it conducted a formal clinical guidance meeting with the U.S. FDA to determine the most expeditious U.S. registration pathway for BiovaxID™, its personalized cancer vaccine for... More...>>
07/30/20129:45AMBWBiovest Advances Process Seeking European Marketing Approval for BiovaxID™ Personalized Lymphoma Vaccine
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the European Medicines Agency (EMA) has notified Biovest regarding the official designation of the Rapporteur and Co-Rapporteur for BiovaxID, a personalized cancer vaccine for... More...>>
07/19/20128:15AMBWMax Planck Institute Presents Study Positioning Biovest Bioreactor Systems as Potential Novel Viral Vaccine Manufacturing Pla...
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the Max Planck Society recently hosted a research seminar in Berlin, Germany at which the Max Planck Institute for Dynamics of Complex Technical Systems (Magdeburg, Germany) presented... More...>>
07/12/20129:45AMBWBiovest’s Eligibility to Seek EU Marketing Approval for its BiovaxID Cancer Vaccine as Orphan Drug Confirmed by EMA
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that in response to Biovest’s notice of intent to file for marketing approval previously submitted to the European Medicines Agency (EMA), the EMA has provided formal notification... More...>>
07/11/201212:29PMDJNRegistration Effectiveness Orders Issued by the SEC
The following table includes registration statements and post-effective amendments that were declared effective by the Securities and Exchange Commission on the most recently completed business day. The Securities Act of 1933 requires companies offering securities to file a registration statement with the SEC that discloses... More...>>
06/20/20127:45AMBWBiovest Initiates Formal Regulatory Approval Process for BiovaxID® Cancer Vaccine in Europe
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that formal notification was submitted to the European Medicines Agency (EMA) informing of Biovest’s intent to file a Marketing Authorization Application (MAA) seeking approval in... More...>>
06/07/20128:15AMBWNCI Study Demonstrates Significant Overall Survival & Time-to-Next-Treatment Benefits for BiovaxID® Cancer Vaccine Following...
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from... More...>>
05/31/20123:13PMBWBiovest Interviewed by OneMedRadio; Discusses Key Milestones Expected to Establish BiovaxID® as the World’s First Personal...
Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that Brett Johnson, President and Executive Editor of OneMedPlace interviewed Biovest’s President and CEO, Samuel S. Duffey, and its Senior Vice President, Product Development... More...>>
05/29/20121:30PMBWBiovest Names Dr. Eduardo Sotomayor, Chair of Dept of Malignant Hematology at Moffitt Cancer Center, to its Scientific Adviso...
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that Biovest has named Eduardo M. Sotomayor, M.D. to its Scientific Advisory Board (SAB). The Biovest SAB represents a group of preeminent physicians and doctors from the fields of... More...>>
05/18/201210:24AMBWBiovest Announces BiovaxID® ASCO Abstract Available On-line; NCI to Present Cancer Vaccine Data from Mantle Cell Lymphoma St...
Biovest International, Inc. (OTCQB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: ABPI), today announced that an abstract reporting new data from the BiovaxID® Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with... More...>>
05/16/20129:45AMBWBiovest Retains Ferghana Partners to Evaluate Strategic Transactions
Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today announced that Biovest has retained Ferghana Partners as the Company’s strategic transaction advisor to evaluate/implement creative financings and partnering opportunities on a regional or global... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq abpi141023 01:19